The safety and efficacy of Celgene's CAR T cell therapies are under investigation and have not been established. There is no guarantee that these agents will receive health authority approval or become commercially available in any country for the uses being investigated.

Cancer Immune Response

Refresh your knowledge about the immune response to cancer, and how cancer can evade detection

CAR T Science

Learn about the science behind CAR T cell therapies

B Cell Malignancies

Learn about unmet needs in select B cell malignancies

CAR T Process

Learn what the CAR T therapy process may involve for you and your patients

References

  • Abate-Daga D, Davila ML. Mol Ther Oncolytics. 2016;3:16014.
  • Abbas AK, Lichtman AH, Pillai S. Cellular and Molecular Immunology. 9th ed. Philadelphia, PA: Saunders Elsevier; 2018.
  • Ajina A, Maher J. Mol Cancer Ther. 2018;17:1795-1815.
  • Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell. 4th ed. 2002;1589.
  • American Cancer Society. Accessed September 29, 2018.
  • American Cancer Society. Accessed September 6, 2018.
  • American Society of Clinical Oncology. Accessed February 22, 2019.
  • Batlevi CL, Matsuki E, Brentjens RJ, Younes A. Nat Rev Clin Oncol. 2016;13:25-40.
  • Bryn T, Yaqub S, Mahic M, Henjum K, Aandahl EM, Tasken K. Int Immunol. 2008;20:235-245.
  • Casulo C, Byrtek M, Dawson KL, et al. J Clin Oncol. 2015;33:2516-2523.
  • ClinicalTrials.gov. Accessed September 29, 2018.
  • ClinicalTrials.gov. Accessed September 29, 2018.
  • Coiffier B, Thieblemont C, Van Den Neste E, et al. Blood. 2010;116:2040-2045. doi:10.1182/blood-2010-03-276246.
  • Crump M, Neelapu SS, Farooq U et al. Blood. 2017;130:1800-1808.
  • D’Aloia MM, Zizzari IG, Sacchetti B, et al. Cell Death Dis. 2018;9:282.
  • Dai H, Wang Y, Lu X, Han W. J Natl Cancer Inst. 2016;108:1-14.
  • Davila ML, Brentjens R, Wang X, Rivière I, Sadelain M. Oncoimmunology. 2012;1:1577-1583.
  • Dong C, Martinez GJ. Nat Rev Immunol. 2010. Poster.
  • Dotti G, Gottschalk S, Savoldo B, et al. Immunol Rev. 2014;257:107-126.
  • Eshhar Z. Hum Gene Ther. 2014;25:773-778.
  • Facon T, Dimopoulos MA, Dispenzieri A, et al. Blood. 2018;131:301-310.
  • Federico M, Bellei M, Marcheselli L, et al. J Clin Oncol. 2009;27:4555-4562.
  • Fesnak A, Lin C, Siegel DL, Maus MV. Transfus Med Rev. 2016;30:139-145.
  • Finn OJ. Ann Oncol. 2012;23:viii6-viii9.
  • Friedberg JW. Hematology. 2011;498-505.
  • Gertz MA, Dingli D. Blood. 2014;124:882-890.
  • Gisselbrecht C, Schmitz N, Mounier N, et al. J Clin Oncol. 2012;30:4462-4469.
  • Golubovskaya V, Wu L. Cancers. 2016;8:36. doi:10.3390/cancers8030036.
  • Hartmann J, Schüßler-Lenz M, Bondanza A, Buchholz, CJ. EMBO Mol Med. 2017;9:1183-1197.
  • Hiddeman W, Cheson BD. Leukemia. 2014;28:1388-1395.
  • Hunger SP, Mullighan CG. N Engl J Med. 2015;373:1541-1552.
  • Janeway CA Jr, Travers P, Walport M, Shlomchik MJl. Immunobiology. 5th ed. 2001;258.
  • Kawalekar OU, O'Connor RS, Fraietta JA, et al. Immunity. 2016;44:380-390.
  • Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. Nat Rev Clin Oncol. 2016;13:273-290.
  • Laidlaw BJ, Craft J, Kaech SM. Nat Rev Immunol. 2016;16:102-111. doi:10.1038/nri.2015.10.
  • LeBien TW, Tedder TF. Blood. 2008;112:1570-1580.
  • Lee DW, Barrett DM, Mackall C, Orentas R, Grupp SA. Clin Cancer Res. 2012;18:2780-2791.
  • Lee DW, Santomasso BD, Locke FL, et al. Biol Blood Marrow Transplant. 2019;25:625-638. doi:10.1016/j.bbmt.2018.12.758.
  • Luckheeram RV, Zhou R, Verma AD, et al. Clin Dev Immunol. 2012;2012:925135.
  • Mahnke YD, Brodie TM, Sallusto F, et al. Eur J Immunol. 2013;43:2797-2809.
  • Maus MV, June CH. Clin Cancer Res. 2016;22:1875-1884.
  • Maus MV, Levine BL. Oncologist. 2016;21:608-617.
  • Medscape. Accessed March 19, 2018.
  • National Cancer Institute. Accessed February 22, 2019.
  • Nature. Accessed November 21, 2018.
  • Nature. Accessed November 21, 2018.
  • Neelapu SS, Tummala S, Kebriaei P, et al. Nat Rev Clin Oncol. 2018;15:47-62.
  • News release. Osaka, Japan: TC BioPharm; February 7, 2018. Accessed September 29, 2018.
  • News release. Richmond, CA: Sangamo Therapeutics; October 1, 2018. Accessed February 12, 2019.
  • News release. Silver Spring, MD: Food and Drug Administration; October 18, 2017. Accessed January 11, 2019.
  • Nijhof IS, van de Donk NWCJ, Zweegman S, et al. Drugs. 2018;78:19-37.
  • Nooka AK, Nabhan C, Zhou X, et al. Ann Oncol. 2013;24:441-448.
  • Novartis. Accessed October 18, 2018.
  • Park JH, Brentjens RJ. Discov Med. 2010;9:277-288.
  • Park JH, Geyer MB, Brentjens RJ. Blood. 2016;127:3312-3320.
  • Philip T, Guglielmi C, Hagenbeek A, et al.N Engl J Med. 1995;333:1540-1545.
  • Porter DL, Hwang WT, Frey NV, et al. Sci Transl Med. 2015;7:303ra139.
  • Prescribing information. East Hanover, NJ: Novartis; August 2017.
  • Prescribing information. Santa Monica, CA: Kite Pharma; October 2017.
  • Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas V.2.2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed April 15, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org.
  • Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma V.4.2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed April 15, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org.
  • Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma V.2.2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed January 29, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org.
  • Roberts ZJ, Better M, Bot A, Roberts MR, Ribas A. Leuk Lymphoma. 2018;59:1785-1796. doi:10.1080/10428194.2017.1387905.
  • Sadelain M, Brentjens R, Rivière I. Cancer Discov. 2013;3:388-398.
  • Sebban C, Brice P, Delarue R, et al. J Clin Oncol. 2008; 26:3614-3620.
  • Shedlock DJ, Shen H. Science. 2003;300:337-339.
  • Showalter A, Limaye A, Oyer JL, et al. Cytokine. 2017;97:123-132.
  • Shustik C, Bence-Bruckler I, Delage R, et al. Ann Hematol. 2017;96:1185-1196.
  • Simon B, Wiesinger M, März J, et al. Int J Mol Sci. 2018;19:2365.
  • Sonneveld P, Broijl A. Haematologica. 2016;101:396-406.
  • Stenner F, Renner C. Front Oncol. 2018;8:219.
  • Strati P. Lancet Haematol. 2017;4:e97-e98.
  • Surveillance, Epidemiology, and End Results (SEER) Program. Accessed February 15, 2018.
  • Surveillance, Epidemiology, and End Results (SEER) Program. Accessed February 15, 2018.
  • Surveillance, Epidemiology, and End Results (SEER) Program. Accessed February 15, 2018.
  • Surveillance, Epidemiology, and End Results (SEER) Program. Accessed February 15, 2018.
  • Surveillance, Epidemiology, and End Results (SEER) Program. Accessed February 15, 2018.
  • Surveillance, Epidemiology, and End Results (SEER) Program. Accessed November 26, 2018.
  • Surveillance, Epidemiology, and End Results (SEER) Program. Accessed September 29, 2018.
  • Surveillance, Epidemiology, and End Results (SEER) Program. Accessed September 29, 2018.
  • Surveillance, Epidemiology, and End Results (SEER) Program. Accessed November 26, 2018.
  • Surveillance, Epidemiology, and End Results (SEER) Program. Accessed November 26, 2018.
  • Surveillance, Epidemiology, and End Results (SEER) Program. Accessed November 26, 2018.
  • Surveillance, Epidemiology, and End Results (SEER) Program. Accessed November 26, 2018.
  • Surveillance, Epidemiology, and End Results (SEER) Program. Accessed November 26, 2018.
  • Swann JB, Smyth MJ. J Clin Invest. 2007;117:1137-1146.
  • Tai YT, Anderson KC. Immunotherapy. 2015;7:1187-1199.
  • Tai YT, Mayes PA, Acharya C, et al. Blood. 2014;123:3128-3138.
  • Teras LR, DeSantis CE, Cerhan JR, et al. CA Cancer J Clin. 2016;66:443-459.
  • ThemoFisher. Accessed September 29, 2018.
  • Thompson PA, Tam CS, O'Brien SM et al. Blood. 2016;127:303-309.
  • Turtle CJ, Hanafi LA, Berger C, et al. J Clin Invest. 2016;126:2123-2138.
  • Van Den Neste E, Schmitz N, Mounier N, et al. Bone Marrow Transplant. 2016;51:51-57.
  • Wang X, Rivière I. Mol Ther–Oncolytics. 2016;3:16015. doi:10.1038/mto.2016.15.
  • Watanabe N, Bajgain P, Sukumaran S, et al. Oncoimmunology. 2016;5:e1253656.
  • Wu YL, Ding YP, Tanaka Y, et al. Int J Biol Sci. 2014;10:119-135.
  • Zhao Z, Condomines M, van der Stegen SJ, et al. Cancer Cell. 2015;28:415-428.

This website is intended for US healthcare professionals only. Are you a US healthcare professional?

NO
YES